Spectranetics starts Turbo elite post-marketing trial
This article was originally published in Clinica
Colorado-based Spectranetics has begun a German trial of its Turbo elite laser catheters in combination with Turbo-Booster. The PATENT trial is a prospective registry of 100 patients to assess arterial patency as measured by duplex ultrasound at intervals up to 12 months after the procedure. It will also assess the device's safety. The Colorado Springs firm's Turbo elite line of laser catheters was approved by the FDA for the treatment of all stenoses and occlusions in the leg arteries in July.